Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Regardless of adherence to weekly Wegovy (semaglutide) injections, adults with obesity who received a higher dose of the medication lost an average of 18.7% of their body weight. More than 1,400 ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Miracle drug innovations — such as those that sparked the meteoric rise of Wegovy and Zepbound — could come every couple of ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

7.2mg Wegovy demonstrated statistically significant and superior weight loss abilities at week 72. In the trial, 1,407 obese adult subjects were randomised to receive once-weekly treatments ...